Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence
Cancer Letters · 2026-12 · 663 · 218902
DOI: 10.1016/j.canlet.2026.218902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Rong Xiao und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Die Arbeit nennt 79 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Advanced-stage cholangiocarcinoma (CCA) frequently develops resistance to chemotherapy, highlighting an urgent unmet need for novel therapeutic strategies. Here, we analyzed 16 pairs of CCA and adjacent non-tumor tissues, and demonstrated that dysregulation of the cell cycle machinery is a hallmark of CCA, closely associated with chemoresistance and poor prognosis. Targeting aberrant cell cycle regulation therefore represents a promising approach to improve current treatment outcomes. We identify the CDC7 inhibitor XL413 as an effective agent capable of re-sensitizing gemcitabine-resistant tumors across multiple preclinical models of CCA. Mechanistic analyses, including transcriptomic profiling, reveal that combination therapy activates senescence-associated pathways, with therapeutic efficacy is mediated via a ROS-DNA damage-senescence cascade. Notably, synergistic induction of cellular senescence is observed in CCA cells upon co-treatment with a CDC7 inhibitor and gemcitabine. Collectively, these findings provide robust preclinical evidence supporting the combination of gemcitabine and CDC7 inhibitors as a viable therapeutic strategy to enhance the clinical management of CCA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- Cancer and Stem Cell Biology Program, Duke-NUS Medical School, 169857, Singapore.
- Hainan Academy of Medical Science, Hainan Medical University, Haikou, China.
- Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
- The Joint Research Center of Guangzhou University and Keele University for Gene Interference and Application, School of Life Science, Guangzhou University, Guangzhou, 510006, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: zhangyuj@sysucc.org.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xiao, R., Hong, J. H., Wang, P., Zhong, Y., Ye, Z., Hao, Z., Gao, J., Jiang, Y., Peng, Y., Chen, S., Yin, J., Liu, L., Xiong, Q., Zhang, Y., Li, M., Chen, J., & Tan, J. (2026). Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence. Cancer Letters, 663, 218902. https://doi.org/10.1016/j.canlet.2026.218902
Vancouver
Xiao R, Hong JH, Wang P, Zhong Y, Ye Z, Hao Z, et al. Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence. Cancer Letters. 2026;663:218902. doi:10.1016/j.canlet.2026.218902
BibTeX
@article{Xiao2026,
author = {Xiao, Rong and Hong, Jing Han and Wang, Peili and Zhong, Yi and Ye, Zhiwei and Hao, Ziyu and Gao, JiuPing and Jiang, Yu and Peng, Yu and Chen, Siyu and Yin, Jiaxin and Liu, Lizhen and Xiong, Qiqing and Zhang, Yaojun and Li, Mei and Chen, Jianfeng and Tan, Jing},
title = {Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence},
journal = {Cancer Letters},
year = {2026},
volume = {663},
pages = {218902},
doi = {10.1016/j.canlet.2026.218902}
}
EUVIMED